<DOC>
	<DOCNO>NCT01542684</DOCNO>
	<brief_summary>The goal clinical research study learn combination azacitidine GM-CSF help control MDS . The safety drug also study . Azacitidine design block certain protein stop function tumor-fighting gene . By block `` bad '' protein , tumor-fighting gene may able work well . Granulocyte-macrophage colony-stimulating factor ( GM-CSF ) design help produce white blood cell . This may help fight infection .</brief_summary>
	<brief_title>Study Azacytidine Followed GM-CSF Patients With Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , Days 1-4 every cycle , receive azacitidine vein 15-30 minute . You may receive drug help prevent nausea vomit receive dose azacitidine . On Days 5-7 every cycle , receive GM-CSF vein 15 minute injection . Each study cycle 4-6 week , depend study doctor 's decision . Study Visits : One ( 1 ) time week every cycle , blood ( 2-3 teaspoon ) draw routine test . At time , doctor think need , bone marrow aspirate check status disease . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your follow-up visit per standard care disease . This investigational study . Both azacitidine GM-CSF FDA approve commercially available treatment MDS . The study drug combination treat MDS consider investigational . Up 40 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Patients low intermediate1risk MDS accord International Prognostic Scoring System ( IPSS ) classification 2 . Signed informed consent indicate patient aware investigational nature study keep policy UT MD Anderson Cancer Center . 3 . Age &gt; /= 18 year old . 4 . Prior therapy growth factor support , lenalidomide , investigational agent allow . 5 . Previously untreated patient eligible study . 1 . Any previous adverse reaction ( &gt; /= Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 ) GMCSF . 2 . Prior treatment azacytidine decitabine . 3 . Unresolved diarrhea &gt; /= CTCAE grade 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Azacytidine</keyword>
	<keyword>5-Azacytidine</keyword>
	<keyword>5-AZA</keyword>
	<keyword>Vidaza</keyword>
	<keyword>5-AZC</keyword>
	<keyword>Aza-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Sargramostim</keyword>
	<keyword>Leukine</keyword>
</DOC>